MK2578 for Anemia in ESA-Naive CKD Patients

Phase 2, randomised, open-label trial of MK2578 in anemia (4 arms), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Hemoglobin Level at 4 weeks, Number of Participants With Composite Events of Death, Myocardial Infarction and Cerebrovascular Accident, Serious Events of Unstable Angina, Transient Ischemic Attack, Arrythmia and Congestive… at 16 weeks and 4 more. Started Nov 2009; status: terminated.